Development of PRO-140 (Leronlimab) as a treatment for COVID-19 [electronic resource] / Jacob Lalezari.
Material type:![Sound](/opac-tmpl/lib/famfamfam/MU.png)
Audio interview.
Title from title frames.
Contents: Previous indications for Leronlimab -- Leronlimab is a CCR5 receptor antagonist -- CCR5 receptor function in inflammation and disease -- Clinical limitations of blocking CCR5 receptors -- How will Leronlimab be used in the clinic? -- When can we expect a preliminary approval?
Access restricted to subscribers.
Mode of access: World Wide Web.